News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Announces Eight Abstracts Selected for Presentation at 2010 AACR Annual Meeting

BOULDER, Colo., Apr 12, 2010 (BUSINESS WIRE) --Array BioPharma Inc. (NASDAQ: ARRY) today announced that eight abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC. Presentations will disclose new findings about its anti-cancer programs: ARRY-162, ARRY-543, AZD6244 (ARRY-886) and three emerging programs for RAF, Chk1 and mTor inhibition.

The abstracts can be accessed through the AACR website, http://www.aacr.org. Abstract titles are provided below, however, please note that according to AACR policy, all data is embargoed until the time of the beginning of the presentation. All posters and presentations will be available as a PDF after they are presented on Array's website at http://www.arraybiopharma.com.

ARRY-162 / MEK Inhibitor:

  • Abstract # 3855 (Apr. 20, 11:25 - 11:40 AM; Room 204): Investigation of the growth inhibitory activity of the MEK inhibitor ARRY-438162 in combination with everolimus in a variety of KRas and P13K pathway mutant cancers
  • Abstract # 2514 (Apr. 19, 2:00 - 5:00 PM; Exhibit Hall A-C, Poster Section 22): ARRY-162, A Potent and Selective MEK 1 / 2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy
  • Abstract # 2515 (Apr. 19, 2:00 - 5:00 PM; Exhibit Hall A-C, Poster Section 22): Preclinical Development of ARRY-162, A Potent and Selective MEK 1 / 2 Inhibitor

ARRY-543 / ErbB-2/EGFR Inhibitor:

  • Abstract # 3610 (Apr. 20, 9:00 AM - 12:00 PM; Exhibit Hall A-C, Poster Section 26): Pan-ErbB inhibition by ARRY-334543 is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors

AZD6244 (ARRY-886) / MEK Inhibitor (partnered with AstraZeneca):

  • Abstract # 4434 (Apr. 20, 2:00 - 5:00 PM; Exhibit Hall A-C, Poster Section 22): Combined targeting of Aurora B (AZD1152) and MEK 1 / 2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo
  • Abstract # 5035 (Apr. 21, 8:00 - 11:00 AM; Exhibit Hall A-C, Poster Section 8): The MEK inhibitor AZD6244 is active in GNAQ mutant ocular melanoma cells

RAF Program (partnered with Genentech):

  • Abstract # 5753 (Apr. 21, 9:55 - 10:10 AM; Room 204): RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Chk1 Program:

  • Abstract # 3874 (Apr. 20, 2:00 - 5:00 PM; Exhibit Hall A-C, Poster Section 1): Single-agent Chk1inhibition is anti-proliferative in leukemia cells in vitro and in vivo

mTOR Program:

  • Abstract # 4484 (Apr. 20, 2:00 - 5:00 PM; Exhibit Hall A-C, Poster Section 24): AR-mTOR-26 - A potent, selective mTORC 1 / 2 kinase inhibitor for the treatment of malignancy

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to http://www.arraybiopharma.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our potential to earn future milestone and royalty payments under our collaboration agreements, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our ability to partner our proprietary drug candidates for up front fees, milestone and/or royalty payments, and our future plans to progress and develop our proprietary programs. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array BioPharma Inc. to meet objectives tied to milestones and royalties; our ability to attract and retain experienced scientists and management. We are providing this information as of April 12, 2010. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com